Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Vertex makes and sells medicines that treat the underlying cause of cystic fibrosis, and is expanding into other serious diseases.
Vertex Pharmaceuticals is a drugmaker that turned one of the cruelest inherited diseases into a manageable condition. Its medicines treat cystic fibrosis, a genetic disorder that slowly clogs the lungs and digestive system. For decades, CF care mostly meant fighting symptoms. Vertex's drugs attack the root cause, the faulty protein sitting on the surface of cells, and that shift changed what a CF diagnosis means for patients.
The business works like this: Vertex invents the drug, runs years of clinical trials to prove it is safe and effective, and then sells it, mostly in the United States and Europe, at a very high price per patient per year. Insurers and government health programs pay, because the alternative for these patients is relentless decline. That pricing power is the engine of the whole company. Vertex has no real competitor in CF, which gives it unusual freedom to set prices. It also invites criticism: the drugs cost hundreds of thousands of dollars a year in the U.S., and health systems in other countries have pushed back hard on the price. The company is not standing still. It has poured money into a second act outside CF, most notably a pain drug called Journavx, approved in early 2025 as the first new kind of non-opioid painkiller in decades. That matters because it offers an alternative to addictive opioids for moderate to severe pain. Vertex is also developing treatments for kidney disease, diabetes, and other conditions. The danger is obvious: if CF revenue ever slips, or a rival finally cracks the code, the whole story changes.
In 1989, Joshua Boger left a safe job at the giant drug company Merck because he believed medicines could be designed on purpose, atom by atom, instead of stumbled upon by testing thousands of random chemicals. He and Kevin Kinsella started Vertex to do exactly that, making it one of the first biotech firms built on this idea of rational drug design. The bet was that understanding the disease first, then building the molecule to fit it, would beat brute-force chemistry.
For years Vertex was a promise without a hit, and then in 2011 came telaprevir, sold as Incivek, a hepatitis C drug that became the fastest launch in drug history, pulling in nearly a billion dollars in its first year and giving Vertex its first-ever annual profit.
While Incivek was flying off shelves, Vertex had quietly been working since 2007 on a different disease: cystic fibrosis, where a faulty gene makes the body clog its own lungs with thick mucus. After 13 years of work with the Cystic Fibrosis Foundation, that bet paid off in 2012 with Kalydeco, the first drug to treat the underlying cause rather than just the symptoms.
The triumph did not last. Gilead's Sovaldi came along and cured nine out of ten hepatitis C patients, making Incivek look like a blunt tool, and sales collapsed almost overnight. By 2014 Vertex stopped selling Incivek altogether, out-innovated in the very market that had made it famous, and suddenly faced a crisis.
Out of that crisis came a new direction. In 2015 Vertex partnered with CRISPR Therapeutics to use gene editing, a way of cutting and correcting DNA itself, on genetic diseases, and sickle cell disease fit the company's strategy perfectly. It was a long shot, but it planted the seed for something remarkable.
The cystic fibrosis thread that started with Kalydeco kept growing. In 2019 came Trikafta, a triple combination pill, and after its label was widened it became the medicine almost every cystic fibrosis patient takes, turning the disease into Vertex's dominant business. The bold early bet on CF had become the company's beating heart.
In 2024 Vertex spent 4.9 billion dollars to buy Alpine Immune Sciences, mostly for one experimental drug called povetacicept that targets autoimmune kidney conditions like IgA nephropathy. It was a step into a whole new disease area, with a regulatory decision expected on it by late 2026.
In 2025 three big things landed at once: Journavx, a non-opioid pain medicine that could offer an alternative to addictive pills, was approved in the U.S.; Alyftrek, an easier once-a-day cystic fibrosis triple combination, launched; and Casgevy, the gene therapy born from that CRISPR partnership, began reaching sickle cell and beta thalassemia patients as the world's first approved CRISPR gene-editing treatment.
Vertex closed its biggest deal ever in 2026, buying Crinetics Pharmaceuticals for roughly 10 billion dollars, bringing in PALSONIFY for the hormone disorder acromegaly and another experimental drug, together with more than 5 billion dollars in potential peak sales. With that, rare endocrine diseases became the company's fifth pillar of growth, standing beside cystic fibrosis, blood disorders, acute pain and kidney disease.
Vertex spends heavily on research, which is the price of admission in biotech, and it is profitable enough to fund that from its own cash. The bet investors are watching is whether the company can repeat its CF magic somewhere much bigger, like pain. Cystic fibrosis is a small patient population. Pain is enormous. That is the whole thesis in one line.
Saved answer · last researched 24 Oct 2026